What is Karyopharm Therapeutics's market cap?

Karyopharm Therapeutics (KPTI) has a market capitalization of $160.7M and trades on NASDAQ.

Who are Karyopharm Therapeutics's competitors?

Karyopharm Therapeutics's key competitors include Amgen Inc., Johnson & Johnson, PUMA BIOTECHNOLOGY INC, and others. These companies compete in similar markets and product categories.

Who does Karyopharm Therapeutics partner with?

Karyopharm Therapeutics's notable partners include Menarini Group, Antengene Therapeutics Limited, Bristol-Myers Squibb Company, and others.

Where is Karyopharm Therapeutics headquartered?

Karyopharm Therapeutics is headquartered in United States of America and employs approximately 325 people. It has been publicly traded since 2013.

Karyopharm Therapeutics

KPTI

Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on the discovery and development of first-in-class drugs directed against nuclear export for cancer treatment.

Market cap

$160.68M+359%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$35.1MBeat by $3.7M EPS-$1.24Beat by $0.21

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$33.6M

EPS estimate-$1.31

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Amgen$203.07B+25.3%

Exelixis$14.0B+15.9%

Opko Health$936.3M-12.5%

Puma Biotechnology$406.7M+145%

X4 Pharmaceuticals$371.6M+2,330%

OnKure Therapeutics, Inc.$163.6M+68.7%

Karyopharm Therapeutics$160.7M+326%

By revenue growth

Amgen+9.1%

Johnson & Johnson+8.1%

Exelixis+3.3%

Opko Health-11.5%

By net margin

Exelixis35.08%+7.1pp

Johnson & Johnson21.48%-3.5pp

Amgen20.96%+3.6pp

Opko Health-12.4%+14.3pp

Profile

Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on the discovery and development of first-in-class drugs directed against nuclear export for cancer treatment. The company's core value proposition centers on its proprietary XPO1 inhibition technology, which restores tumor suppressor proteins to the nucleus to combat various hematological and solid tumor malignancies.

Competitive position

A pioneer in nuclear export inhibition with the first oral XPO1 inhibitor to receive FDA approval.

GeographiesUnited States, Europe, China, Canada, Israel, Japan

Customer segmentsHealthcare Providers, Pharmaceutical Partners, Patients

Business modelProduct-based, Licensing and Royalties, R&D

SuppliersContract manufacturing organizations, Raw material suppliers, Clinical research organizations

CustomersSpecialty pharmacies, Wholesale distributors, International licensing partners, Cancer patients

CountryUnited States of America

Listed2013

Employees325.0

CEORichard A. Paulson

SectorHealthcare

IndustryBiotechnology

Websitekaryopharm.com

FilingsSEC EDGAR

Questions, answered.

What is Karyopharm Therapeutics's market cap?: Karyopharm Therapeutics (KPTI) has a market capitalization of $160.7M and trades on NASDAQ.
Who are Karyopharm Therapeutics's competitors?: Karyopharm Therapeutics's key competitors include Amgen Inc., Johnson & Johnson, PUMA BIOTECHNOLOGY INC, and others. These companies compete in similar markets and product categories.
Who does Karyopharm Therapeutics partner with?: Karyopharm Therapeutics's notable partners include Menarini Group, Antengene Therapeutics Limited, Bristol-Myers Squibb Company, and others.
Where is Karyopharm Therapeutics headquartered?: Karyopharm Therapeutics is headquartered in United States of America and employs approximately 325 people. It has been publicly traded since 2013.